Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats

Behavioural Pharmacology

Volumn 7, Issue 8, 1996, Pages 820-826

  Gosselin, G ^a   Oberling, P ^b   Di Scala, G ^a  

^a CNRS   (France)

^b INSERM   (France)

Author keywords

atypical antipsychotics; conditioned emotional response; dopamine; hyperactivity; latent inhibition; olanzapine; rat; schizophrenia; serotonin

Indexed keywords

DEXAMPHETAMINE; NEUROLEPTIC AGENT; OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG ANTAGONISM; EMOTION; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT INHIBITION; LEARNING; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; RAT; REINFORCEMENT; SCHIZOPHRENIA;

EID: 0030439347     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Amt J (1995) Differential effects of classical and new antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. European Journal of Pharmacology, 283, 55-62.
2. Baruch I, Hemsley DR and Gray JA (1988) Differential performance of acute and chronic schizophrenics in a latent inhibition task. Journal of Nervous and Mental Disease, 176, 598-606.
3. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. Journal of Clinical Psychopharmacology, 15, 24S-29S.
4. Bruhwyler J, Chleide E and Mercier M (1990) Clozapine: an atypical neuroleptic. Neuroscience and Biobehavioral Reviews, 14, 357-363.
5. Bymaster FR, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P and Wong DT (1996a) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87-96.
6. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology, 124, 87-94.
7. Christison GW, Atwater GE, Dunn LA and Kilts CD (1988) Haloperidol enhancement of latent inhibition: relation to therapeutic action? Biological Psychiatry, 23, 746-749.
8. Costall B and Naylor RJ (1977) Mesolimbic and extrapyramidal sites for the mediation of the stereotyped behaviour patterns and hyperactivity by amphetamine and apomorphine in the rat. Advanced Behavioral Biology, 21, 47-76.
9. 3 receptor antagonist. GR38032F, on raised dopaminergic activity in the mesolimbic system of rat and marmoset brain. British Journal of Pharmacology, 92, 881-894.
10. Creese I, Burt D and Snyder S (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antipsychotic drugs. Science, 192, 481-483.
11. Dixon NJ (1993) BMDP statistical software. University of California Press, Los Angeles.
12. Dunn LA and Scibilia RJ (1994) Clozapine and olanzapine enhance latent inhibition at low, but not high doses in rats. Society for Neuroscience Abstracts, 20, 226.
13. Dunn LA, Atwater GE and Kilts CD (1993) Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology, 112, 315-323.
14. Feldon J and Weiner I (1991a) An animal model of attention deficit. In: Neuromethods, Vol. 18: Animal Models in Psychiatry I (Eds AA Boulton, GB Baker and MT Martin-Iverson), pp. 313-361. Humana Press, Clifton, NJ.
15. Feldon J and Weiner I (1991b) The latent inhibition model of schizophrenic disorder haloperidol and sulpiride enhance rat's ability to ignore irrelevant stimuli. Biological Psychiatry, 29, 635-646.
16. Gray JA, Feldon J, Rawlins JNP, Hemsley DR and Smith AD (1991) The neuropsychology of schizophrenia. Behavioral and Brain Sciences, 14, 1-84.
17. Kane JM (1993) New antipsychotic drugs: a review of their pharmacology and therapeutic potential. Drugs, 46, 585-593.
18. Killcross AS and Robbins TW (1993) Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology, 110, 479-489.
19. Lauener H (1962) Conditioned suppression in rats and the effect of pharmacological agents thereon. Psychopharmacologia, 4, 311-325.
20. Lubow RE (1973) Latent inhibition. Psychological Bulletin, 79, 398-407.
21. Lubow RE (1989) Latent Inhibition and Conditioned Attention Theory. Cambridge University Press, New York.
22. Meltzer HY (1992) The importance of serotonin-dopamine interactions in the action of clozapine. British Journal of Psychiatry, 160 (suppl. 17), 22-29.
23. Moore NA, Tye NC, Axton MS and Risius FC (1992) The behavioural pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics, 262, 545-551.
24. Moore NA, Calligaro DO, Wong DT, Bymaster F and Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs 2, 281-293.
25. Moore NA, Rees G, Sanger G and Tye NC (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behavioural Pharmacology, 5, 196-202.
26. 3 antagonist, facilitates latent inhibition in the rat. Pharmacology, Biochemistry and Behavior, 42, 519-522.
27. Moran PM, Fischer TR, Hitchcock and Moser PC (1996) Effects of clozapine on latent inhibition in the rat. Behavioural Pharmacology, 7, 42-48.
28. 2 antagonist MDL 100,907 on latent inhibition in the rat. Behavioural Pharmacology, 5, 120-121.
29. 2A antagonist. Behavioural Brain Research, 73, 163-167.
30. Solomon P, Crider A, Winkelman JW, Turi A, Kamer RM and Kaplan MJ (1981) Disrupted latent inhibition in the rat with chronic amphetamine and haloperidol-induced hypersensitivity: relationship to schizophrenic attention disorder. Biological Psychiatry, 16, 519-537.
31. Szymansky S, Lieberman J, Pollack S, Munne R, Saffermann A, Kane J, Kronig M and Cooper T (1993) The dopamine-serotonin relationship in clozapine response. Psychopharmacology, 112 (suppl.), S85-S89.
32. Warburton EC, Joseph MH, Feldon J, Weiner I and Gray JA (1994) Antagonism of amphetamine-induced disruption of LI in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology, 114, 657-664.
33. Weinberger DR and Lipska BK (1995) Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophrenia Research, 16, 87-110.
34. Weiner I (1990) Neural substrates of latent inhibition: the switching model. Psychological Bulletin, 108, 442-461.
35. Weiner I and Feldon J (1994) The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action: comment on Dunn, Atwater and Kilts (Psychopharmacology, 1993, 112, 315-323). Psychopharmacology, 116, 1379-380.
36. Weiner I, Lubow RE and Feldon J (1987a) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacology, Biochemistry and Behavior, 30, 871-878.
37. Weiner I, Feldon J and Katz Y (1987b) Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacology, Biochemistry and Behavior, 26, 241-246.
38. Weiner I, Kidron R, Tarrasch R, Arnt J and Feldon J (1994) The effects of the new antipsychotic, sertindole, on latent inhibition in rats. Behavioural Pharmacology, 5, 119-124.